Hualan Biological Engineering, Inc. (002007.SZ) announced that its equity investee Hualan Gene Engineering Co., Ltd. received a notification from the National Pharmaceutical Administration regarding the registration of the pharmaceutical.
According to Zhitong Finance APP, Hualan Biological Engineering, Inc. (002007.SZ) announced that its equity investee Hualan Gene Engineering Co., Ltd. received an acceptance notification from the National Medical Products Administration for the marketing registration of Rituximab Injection (specifications: 500mg/bottle, 100mg/bottle) for domestic production. The National Medical Products Administration reviewed the application for the marketing registration of the above pharmaceutical and decided to accept it.
